Accelerating ADCs with Mythic Therapeutics' Brian Fiske, Ph.D.

Business Of Biotech

We love to hear from our listeners. Send us a message.

Mythic Therapeutics Chief Scientific Officer and co-founder Brian Fiske, Ph.D. broke some unwritten protocol with his rapid and multifaceted transition from academia to industry. He calls his many, and sometimes concurrent, early experiences as an MIT Ph.D. student, a Flagship Ventures Fellow, a Bain consultant, a hospital researcher, and a biopharma consultant indiciative of a young man who didn't want to make decisions. In retrospect, it looks more like the perfect preparatory mix for a guy who's leading a company with a unique approach to a white-hot ADC (antibody-drug conjugate) therapeutics market. On this epsiode of the Business of Biotech, get to know Brian as we peel back the layers to expose what's fueling the rapid rise of Mythic's ADC candidate in non-small cell lung cancer.

Access this and hundreds of episodes of the Business of Biotech videocast under the Listen & Watch tab at bioprocessonline.com.

Subscribe to our monthly Business of Biotech newsletter.
Get in touch with guest and topic suggestions: [e-mail]
Find Matt Pillar on LinkedIn: https://www.linkedin.com/in/matthewpillar/

Κεφάλαια

1. Biotech Business and Entrepreneurial Journey (00:00:00)

2. Navigating Career Transitions and Startup Success (00:09:24)

3. Innovating the ADC Field With Mythic (00:18:14)

4. Building an Enduring Oncology Company (00:31:43)

5. Building an Enduring Oncology Company (00:39:14)

6. Mythic's Strategy in Crowded ADC Space (00:48:55)

7. Mythic Therapeutics (00:55:21)